-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda’s ORZEYFUL Wins Japan Approval For Narcolepsy Type 1 After Phase 3 Studies Show Significant Improvements Across Evaluated Symptoms

Benzinga·08/24/2026 07:29:29
语音播报
  • Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1)
  • Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo
  • Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World